Abstract
Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to toxicity. According to international working group criteria, three patients (16%) responded to treatment. No correlation between VPA serum level, histone acetylation or clinical response was observed.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylation / drug effects
-
Aged
-
Aged, 80 and over
-
Calcitriol / administration & dosage
-
Calcitriol / adverse effects
-
Calcitriol / therapeutic use*
-
Cheilitis / chemically induced
-
Chemical and Drug Induced Liver Injury / etiology
-
Drug Therapy, Combination
-
Fatigue / chemically induced
-
Histones / metabolism
-
Humans
-
Isotretinoin / administration & dosage
-
Isotretinoin / adverse effects
-
Isotretinoin / therapeutic use*
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
-
Pneumonia / chemically induced
-
Protein Processing, Post-Translational / drug effects
-
Treatment Outcome
-
Valproic Acid / administration & dosage
-
Valproic Acid / adverse effects
-
Valproic Acid / therapeutic use*
Substances
-
Histones
-
Valproic Acid
-
Isotretinoin
-
Calcitriol